FINWIRES · TerminalLIVE
FINWIRES

新西兰股市在美伊和平谈判前交易谨慎,股价下跌;新西兰帝王鲑投资公司上调2026财年业绩预期

By

-- 周五,新西兰股市收跌,亚洲股市普遍下跌,投资者尽管在美伊和平谈判前夕以色列和黎巴嫩停火生效,但仍保持谨慎态度。 S&P/NZX 50 指数下跌 1.2%,或 160.4 点,收于 12,905.67 点。 据路透社周四报道,美国总统唐纳德·特朗普表示,美伊下一轮会谈可能在周末举行。 国内方面,新西兰统计局数据显示,经季节性调整后,3 月份新西兰电子信用卡消费额环比增长 1.3%,达到 98.5 亿新西兰元,与上月 1.3% 的增幅持平。 此外,realestate.co.nz 的数据显示,3 月份基督城房产的平均要价与过去三年持平,低于新西兰其他主要城市。 此外,根据新西兰统计局(Stats NZ)发布的精选价格指数报告,3月份新西兰汽油和柴油价格分别较上月上涨近19%和43%。 与此同时,澳新银行研究部(ANZ Research)在一份报告中指出,预计新西兰3月份季度的年通胀率将放缓0.2个百分点至2.9%,略高于此前预测的2.8%,但略低于新西兰储备银行(RBNZ)4月份预测的3%。 在公司新闻方面,新西兰帝王鲑投资公司(NZE:NZK,ASX:NZK)上调了其2026财年的业绩预期,目前预计其调整后的息税折旧摊销前利润(EBITDA)将从此前预测的900万至1500万新西兰元上调至1900万至2700万新西兰元。 Contact Energy(NZE:CEN,ASX:CEN)已申请上市约 500 万股普通股,这些股票是与其收购 King Country Energy 的额外股份相关的。

Related Articles

Research

Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23

AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AES
Australia

Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell

Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%

$CMPX
Sectors

Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision

Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.

$GCM6$GLD